Navigation Links
New agent may enhance effectiveness of radiotherapy
Date:5/13/2014

Scientists from The University of Manchester part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

There is increasing interest in using the body's own immune system to attack tumour cells a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognises foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumour and the number of secondary tumours in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumour shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumours.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumours. These results strong
'/>"/>

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pig stomach mucins are effective as anti-viral agents for consumer products
2. Imaging agents predict breast cancer response to endocrine therapy
3. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
4. New substances 15,000 times more effective in destroying chemical warfare agents
5. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
6. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
7. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
8. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
9. Rilpivirine for HIV: Added benefit for single agent proven
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Investigational agent targets gene signaling pathways to improve response for patients with CLL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 USARAD Holdings Inc. a ... solutions provider, including SecondOpinions.com® – consumer division is ... advanced services. The telemedicine industry pioneer is now ... , Founded and established in 1963 as the ... began as a maternity care hospital with very ...
(Date:9/2/2014)... to announce that the following papers will be ... Congress 2014, taking place in Barcelona, Spain, 30 ... strut biodegradable polymer sirolimus-eluting stent versus durable polymer ... randomised, single-blind, non-inferiority trial, Windecker et al ... surface polymer, and drug release have improved clinical ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 The global ... USD 8,918.8 million by 2020, growing at an estimated ... a new study by Grand View Research, Inc. Peripheral ... plague modification devices are used for treating peripheral arterial ... of atherosclerotic plaques in arteries. These devices are used ...
(Date:9/2/2014)... Denver, Colo. (PRWEB) September 02, 2014 ... reimagined patient care, has been selected from a group ... round of the 2014 PrIME Digital Health Challenge. The ... against one another, Tuesday, Sept. 9th at the CSU ... in 2012, MyRounding is based in Denver, Colo. The ...
(Date:9/2/2014)... Headaches, both chronic and acute ruin lives. They can ... friends, sleeping and just coping well with daily activities. ... worldwide. The medications prescribed for these conditions frequently don’t ... cases of headache and back pain are of a mechanical ... detect and fix the cause. , When a sports ...
Breaking Medicine News(10 mins):Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4Health News:The Lancet: European Society of Cardiology Congress 2014 media alert 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5Health News:MyRounding Selected for Digital Health Venture Showcase Finals Top Three Startups Awarded $50,000 2Health News:Physical Therapists in Houston Learn Pain Relief Techniques 2
... you,re ready to drive again , , WEDNESDAY, Dec. 10 (HealthDay ... wheel again after orthopedic surgery or injury, but knowing when it,s ... , Orthopedic surgeons weigh in on the issue in the December ... , "Deciding when a patient can return to driving is ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Inc., a leading,provider of software and databases for systems ... Singapore Immunology Network (SIgN) has become a,certified GeneGo Center ... MetaCore, training and advanced support. SIgN COE will ... "We are excited ...
... Facilities , , NEW ... process, a proven commitment to clinical quality earned SigmaCare(R) ... Metropolitan Jewish Health System,s (Metropolitan) skilled nursing facilities. ... nationally recognized nonprofit organization, operates Metropolitan Jewish Geriatric Center, ...
... Pharma Services, Goodwill, , , ... NYSE: MDZ ), a leading provider of products and ... fiscal 2008 performance. , Based on preliminary information, MDS ... of $1,210 million to $1,220 million and adjusted EBITDA in the ...
... Care Insurance While They,re Still Healthy Enough to Qualify , ... If you,ve put off getting long term care insurance, ... new administration,s health plan? "I wouldn,t advise it," says Denise ... (LTCFP), one of the nation,s most experienced long term care ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
(Date:9/2/2014)... -- ResMed (NYSE: RMD ) has introduced the ... the United States . The Astral platform is ... support ventilators. ResMed,s new Astral life ... for patients suffering from neuromuscular disease, chronic obstructive pulmonary ... The U.S. launch comes on the heels of Astral,s ...
(Date:9/2/2014)... 2014   Mast Therapeutics, Inc . (NYSE MKT: MSTX) today ... , will present at the Rodman and Renshaw 16 th ... p.m. Eastern time in the Holmes II Salon at The New ... Interested parties can access a live audio webcast and ... . An archived presentation will be available on the web site ...
(Date:9/2/2014)... Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... products marketed as XIAFLEX ® in the U.S. and ... President, Tom Wegman , will present at the following ... Rodman & Renshaw 16 th Annual ... Tuesday, September 9, 2014 at 9:10 a.m. EDT ...
Breaking Medicine Technology:ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... SEATTLE, Jan. 13, 2011 Dendreon Corporation (Nasdaq: ... market and other conditions, $500 million aggregate principal amount of ... an offering registered under the Securities Act of 1933, as ... cash, shares of Dendreon,s common stock (the "Common Stock") or ...
... BURLINGAME, Calif., Jan. 13, 2011 Collaborative Drug Discovery, Inc. ... has extended its previous grant to CDD to create a ... drugs against tuberculosis (TB). The TB bacillus infects approximately one ... 1.5 million people every year. Over the past ...
Cached Medicine Technology:Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 2Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 3Dendreon Announces Offering of $500 Million Convertible Senior Notes Due 2016 4Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations 2
Inquire...
Inquire...
... The compact Allegra X-22 Series is up to ... With a library of 11 rotors, the Allegra X-22 ... Features: Only 18 inches / 46 ... to 22,065 x g 3 different ways to ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: